Screener
Stoke Therapeutics, Inc. STOK Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Deferred revenue - net of current portion | 6,603 | 6,961 |
| Other long-term liabilities | 991 | 1,141 |
| Total long-term liabilities | 7,594 | 8,102 |
| Total liabilities | $48,400 | $65,977 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity | ||
| Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 62,240,347 and 58,921,999 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 6 | 5 |
| Additional paid-in capital | 942,704 | 849,624 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s total liabilities?
- Stoke Therapeutics, Inc. (STOK) reported total liabilities of $48.4M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s total liabilities changed year-over-year?
- Stoke Therapeutics, Inc.'s total liabilities decreased by 14.8% year-over-year, from $56.81M to $48.4M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s total liabilities has grown at a 41.0% compound annual growth rate (CAGR), from $11.85M to $65.98M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Stoke Therapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude